New injection shows promise for Hard-to-Treat cancers
NCT ID NCT07603479
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a shot under the skin, either alone or with standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can an immune booster outsmart brain lymphoma?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?